StreetInsider.com News Articles

This name is poised to transform care in rare bleeding disorders

Sat, 30 May 2026 22:00:00 -0400

Existing treatments for blood disorders like Glanzmann thrombasthenia (GT), Factor VII deficiency (FVIID), and Von Willebrand disease (VWD) require burdensome IV administration during bleeds. But a new treatment designed for subcutaneous prophy dosing—sutacimig—is set to revolutionise the space, and Jefferies thinks the biotech company responsible for the drug will transform care in rare bleeding disorders.

The biotech stock of interest is Hemab Therapeutics (NASDAQ: COAG), initiated at ‘Buy’ with a price target of $39 at Jefferies.

The company aims to develop preventive therapy for conditions in which patients suffer frequent, dangerous bleeding episodes.

Jefferies believes that there are three specific supportive factors making

This name is poised to transform care in rare bleeding disorders

Sat, 30 May 2026 22:00:00 -0400

The biotech stock of interest is Hemab Therapeutics (NASDAQ: COAG), initiated at ‘Buy’ with a price target of $39 at Jefferies.

The company aims to develop preventive therapy for conditions in which patients suffer frequent, dangerous bleeding episodes.

Jefferies believes that there are three specific supportive factors making

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:00:00 -0400

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced that members of the Hemab Therapeutics management team will present and host investor meetings at the 2026 Jefferies Global Healthcare Conference.

2026 Jefferies Global Healthcare Conference
Fireside Chat: Thursday, June 4, 2026 at 9:20 AM ET
Location: New York, NY

A live webcast of the fireside chat will be available for replay under “Events & Presentations” section in the Investors section

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Wed, 27 May 2026 08:00:00 -0400

2026 Jefferies Global Healthcare Conference
Fireside Chat: Thursday, June 4, 2026 at 9:20 AM ET
Location: New York, NY

A live webcast of the fireside chat will be available for replay under “Events & Presentations” section in the Investors section

Evercore ISI Starts Hemab Therapeutics Holdings (COAG) at Outperform

Tue, 26 May 2026 07:40:57 -0400

Evercore ISI analyst Cory K initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Outperform rating.

For an analyst ratings summary and ratings history on Hemab Therapeutics Holdings click here. For more ratings news on Hemab Therapeutics Holdings click here.

Shares of Hemab Therapeutics Holdings closed at $25.89 yesterday.

Wedbush Starts Hemab Therapeutics Holdings (COAG) at Outperform

Tue, 26 May 2026 07:01:00 -0400

(Updated - May 26, 2026 7:01 AM EDT)

Wedbush analyst David Nierengarten initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Outperform rating and a price target of $42.00.

The analyst comments "We view Hemab Therapeutics (NASDAQ: COAG) as a high conviction opportunity within rare coagulation disorders. COAG is developing subcutaneous prophylactic antibody therapies for inherited bleeding disorders where current treatment is dominated by burdensome IV factor replacement or lack approved prophylactic options. The lead asset, sutacimig (HMB-001), is a bispecific antibody that restores clotting capability by recruiting endogenous Factor VII/VIIa

Wedbush Starts Hemab Therapeutics Holdings (COAG) at Outperform

Tue, 26 May 2026 07:01:00 -0400

(Updated - May 26, 2026 7:01 AM EDT)

Wedbush analyst David Nierengarten initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Outperform rating and a price target of $42.00.

Jefferies Starts Hemab Therapeutics Holdings (COAG) at Buy

Tue, 26 May 2026 03:16:11 -0400

Jefferies analyst Maury Raycroft initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Buy rating and a price target of $39.00.

The analyst comments: “COAG is poised to transform care in rare bleeding disorders, similar to what Roche’s Hemlibra did for hemophilia. Aim is to develop preventive therapy in diseases such as Glanzmann thrombasthenia (GT), Factor VII deficiency (FVIID), and Von Willebrand disease (VWD) where patients suffer frequent, dangerous bleeding episodes. COAG is well capitalized w/ pro forma $480M cash w/ runway into 2029 through multiple derisking catalysts. Initiate @ Buy w/ PT $39.

We base our conviction on 3 central

Jefferies Starts Hemab Therapeutics Holdings (COAG) at Buy

Tue, 26 May 2026 03:16:11 -0400

Jefferies analyst Maury Raycroft initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Buy rating and a price target of $39.00.

We base our conviction on 3 central

Goldman Sachs Starts Hemab Therapeutics Holdings (COAG) at Buy

Tue, 26 May 2026 00:52:43 -0400

Goldman Sachs analyst Richard Law initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Buy rating and a price target of $36.00.

The analyst comments: “We initiate coverage on Hemab (COAG) with a Buy rating and $36 PT. Its lead asset, sutacimig, is a bispecific antibody being developed in Ph. 1/2 studies as a prophylactic subcutaneous (SC) treatment for Glanzmann thrombasthenia (GT) and Factor VII deficiency (FVIID) where there are no SC prophylaxis available and no other such assets in development. Sutacimig has shown up to 87% reduction in annualized treated bleed rates in GT and could serve as POC

Goldman Sachs Starts Hemab Therapeutics Holdings (COAG) at Buy

Tue, 26 May 2026 00:52:43 -0400

Goldman Sachs analyst Richard Law initiates coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with a Buy rating and a price target of $36.00.

Form 4 Hemab Therapeutics Holdi For: May 19 Filed by: Kolchinsky Peter

Thu, 21 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260521/26535721.html

Form 10-Q Hemab Therapeutics Holdi For: Mar 31

Thu, 21 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260521/26535056.html

Form 8-K Hemab Therapeutics Holdi For: May 21

Thu, 21 May 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260521/26531367.html

Form 4 Hemab Therapeutics Holdi For: May 12 Filed by: Kolchinsky Peter

Thu, 14 May 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260514/26496734.html

Form 3 Hemab Therapeutics Holdi For: May 04 Filed by: AI Biotechnology LLC

Thu, 14 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260514/26494628.html

Form SCHEDULE 13G Hemab Therapeutics Holdi Filed by: RA CAPITAL MANAGEMENT, L.P.

Mon, 11 May 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20260511/26470858.html

Form 4 Hemab Therapeutics Holdi For: May 07 Filed by: Kolchinsky Peter

Mon, 11 May 2026 17:44:00 -0400

si-local-file:///var/storage/secattach/20260511/26470849.html

Form SCHEDULE 13D Hemab Therapeutics Holdi Filed by: AI DEN-MAB LLC

Mon, 11 May 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260511/26470068.html

Form 8-K Hemab Therapeutics Holdi For: May 08

Mon, 11 May 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260511/26468701.html

Form SCHEDULE 13G Hemab Therapeutics Holdi Filed by: Deep Track Capital, LP

Fri, 08 May 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260508/26461411.html

Form 4 Hemab Therapeutics Holdi For: May 04 Filed by: RA Capital Nexus Fund II, L.P.

Wed, 06 May 2026 19:17:00 -0400

si-local-file:///var/storage/secattach/20260506/26445930.html

Form 4 Hemab Therapeutics Holdi For: May 04 Filed by: Novo Holdings A/S

Wed, 06 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260506/26445148.html

Form 4 Hemab Therapeutics Holdi For: Jan 29 Filed by: MARAGANORE JOHN

Mon, 04 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260504/26426073.html

Form 4 Hemab Therapeutics Holdi For: Jan 29 Filed by: Madigan Catherine

Mon, 04 May 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260504/26426031.html